Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | GSK3B | P49841 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11880888 | 0.84 | RAB9A (0.49) | DAORAB9ASMN1; SMN2MAPTNPC1 | |
| SCHEMBL11844863 | 0.81 | DAO (0.71) | DAORAB9ASMN1; SMN2MAPTNPC1 | |
| SCHEMBL23151886 | 0.80 | MAPT (0.47) | DAORAB9ASMN1; SMN2MAPTNPC1 | |
| SCHEMBL377802 | 0.79 | DAO (0.68) | DAORAB9ASMN1; SMN2MAPTNPC1 | |
| SCHEMBL792551 | 0.79 | DAO (1.00) | DAORAB9ASMN1; SMN2MAPTNPC1 | |
| SCHEMBL9407745 | 0.78 | RAB9A (0.46) | DAORAB9ASMN1; SMN2MAPTNPC1 | |
| SCHEMBL31139879 | 0.78 | MAPT (0.46) | DAORAB9ASMN1; SMN2MAPTNPC1 | |
| SCHEMBL2063137 | 0.78 | DAO (0.61) | DAORAB9ASMN1; SMN2MAPTNPC1 | |
| SCHEMBL28636581 | 0.78 | RAB9A (0.50) | DAORAB9ASMN1; SMN2MAPTNPC1 | |
| SCHEMBL14434109 | 0.77 | DAO (0.54) | DAORAB9ASMN1; SMN2MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119874697-A | Preparation method of thiazole amide derivative and application of thiazole amide derivative in treatment of inflammation | 成都大学 | 2025-04-25 | — | — | CN | claimed |
| CN-117486872-A | Mechanical ball milling synthesis method of aminothiazole compound | 浙江工业大学 | 2024-02-02 | — | — | CN | claimed |
| CN-110759888-A | Synthetic method of 3-acetyl-2, 5-dichlorothiophene | 山东省化工研究院 | 2020-02-07 | — | — | CN | claimed |
| CN-102797043-B | Medicinal molecular fragment library and construction process thereof | Tianli (Tianjin) Technology Co., Ltd. (CN) | 2015-11-25 | — | — | CN | claimed |
| EP-0617038-B1 | Preparation of carbonic anhydrase inhibitors | ALCON LAB INC (US) | 2001-09-05 | — | — | EP | claimed |
| US-6096124-A | Ink compositions | XEROX CORPORATION (US) | 2000-08-01 | — | — | US | claimed |
| EP-0617038-A1 | Preparation of carbonic anhydrase inhibitors | ALCON LABORATORIES, INC. (US) | 1994-09-28 | — | — | EP | claimed |
| US-5344929-A | Preparation of carbonic anhydrase inhibitors | ALCON LABORATORIES, INC. (US) | 1994-09-06 | — | — | US | claimed |
| JP-7002835-A | — | — | None | — | — | JP | disclosed |
| US-20250340532-A1 | HETEROCYCLIC COMPOUND CCR4 INHIBITOR AND USER THEREOF | XIZANG HAISCO PHARMACEUTICAL CO LTD (CN) | 2025-11-06 | — | — | US | disclosed |
| CN-119874697-A | Preparation method of thiazole amide derivative and application of thiazole amide derivative in treatment of inflammation | 成都大学 | 2025-04-25 | — | — | CN | disclosed |
| CN-119874697-A | Preparation method of thiazole amide derivative and application of thiazole amide derivative in treatment of inflammation | 成都大学 | 2025-04-25 | — | — | CN | disclosed |
| EP-4534534-A1 | HETEROCYCLIC COMPOUND CCR4 INHIBITOR AND USER THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2025-04-09 | — | — | EP | disclosed |
| CN-117486872-A | Mechanical ball milling synthesis method of aminothiazole compound | 浙江工业大学 | 2024-02-02 | — | — | CN | disclosed |
| EP-0202903-A2 | Control of ectoparasites | ELI LILLY AND COMPANY (US) | 1986-11-26 | — | — | EP | disclosed |
| EP-0187711-A2 | Octahydroindolizine compounds useful as analgesics | McNeilab, Inc. (US) | 1986-07-16 | — | — | EP | disclosed |
| US-4582836-A | Octahydroindolizine compounds useful as analgesics | MCNEILAB, INC. (US) | 1986-04-15 | — | — | US | disclosed |
| US-4558045-A | CARDIOTONIC AND HYPOTENSIVE ACTIVITY | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1985-12-10 | — | — | US | disclosed |
| US-4489073-A | HYPOTENSIVE AND CARDIOTONIC AGENTS | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1984-12-18 | — | — | US | disclosed |
| EP-0085227-A1 | Thiadiazine derivatives, and pharmaceutical compositions containing them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340532-A1 | HETEROCYCLIC COMPOUND CCR4 INHIBITOR AND USER THEREOF | CCR4, CCR1, CCR3 | DAO 3386/4885RAB9A 2964/4885SMN1; SMN2 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.